PI: Allison King
Contact: Lisa Garrett
garrett_l@wustl.edu
314-362-0051 | Sickle Cell Disease | Sickle Cell Disease Patient Registry (SCDIC-II) (NHLBI) | Enrolling
(pdf – password protected) |
PI: Allison King
Contact: Lisa Garrett
garrett_l@wustl.edu
314-362-0051 | Sickle Cell Disease | The Epidemiology of Silent and Overt Strokes in Adults with Sickle Cell Disease (Global Blood Therapeutics) | Enrolling
(pdf – password protected) |
PI: Allison King
Contact: Lisa Garrett
garrett_l@wustl.edu
314-362-0051 | Sickle Cell Disease | Sickle Cell Disease and CardiovAscular Risk-Red cell Exchange Trial (SCD-CARRE) (NHLBI) | Enrolling
(pdf – password protected) |
PI: Elaine Majerus
Contact: Rachel Cody
rcody@wustl.edu
314-362-7306 | Hemophilia A | A Phase 3 Study of Valoctocogene Roxaparvovec in Hemophilia A Patients (BioMarin Pharmaceutical) | Open |
PI: Elaine Majerus
Contact: Sabrina Barber
s.barber@wustl.edu
314-273-1440 | Hemophilia A | Emicizumab In Patients With Acquired Hemophilia A: Multicenter, Single-Arm, Open-Label Clinical Trial (Genetech) | Enrollment pending
(pdf – password protected) |
PI: Elaine Majerus
Contact: Sabrina Barber
s.barber@wustl.edu
314-273-1440 | Hemophilia A | Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B with inhibitors (Novo Nordisk Pharmaceuticals, Inc.) | Open to enrollment
(pdf – password protected) |
PI: Elaine Majerus
Contact: Sabrina Barber
s.barber@wustl.edu
314-273-1440 | Atypical HUS | Atypical Hemolytic-Uremic Syndrome (aHUS) Registry (Alexion) | Open to enrollment |
PI: Elaine Majerus
Contact: Bill Berger
bergerwb@wustl.edu
314-362-9996 | Bleeding and clotting disorders | CDC Community Counts: Surveillance Project for Patients with Bleeding and Blood Clotting Disorders (CDC Division of Blood Disorders) | Open |
PI: Elaine Majerus
Contact: Sabrina Barber
s.barber@wustl.edu
314-273-1440 | PNH | Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry (Alexion) | Open to enrollment |
PI: Elaine Majerus
Contact: Sabrina Barber
s.barber@wustl.edu
314-273-1440 | PNH | A multicenter, single arm, open-label trial to evaluate efficacy and safety of oral, twice daily iptacopan in adult PNH patients who have Hb≥10 g/dL in response to anti-C5 antibody and switch to iptacopan (Novartis) | Pending enrollment
(pdf – password protected) |
PI: Elaine Majerus
Contact: Bill Berger
bergerwb@wustl.edu
314-362-9996 | Hemophilia/Bleeding | American Thrombosis and Hemostasis Network Data Collection (CDC Division of Blood Disorders) | Open |
PI: Elaine Majerus
Contact: Sabrina Barber
s.barber@wustl.edu
314-273-1440 | Von Willebrand Disease | A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People with Severe Von Willebrand Disease (VWD) (American Thrombosis and Hemostasis Network (ATHN)) | Open to enrollment
(pdf – password protected) |
PI: Stephen Oh
Contact: Karyn Gordon
kdgordon@wustl.edu
314-362-0156 | Myelofibrosis | Extended Access of Momelotinib in Adults with Myelofibrosis (352-4365) (Gilead) | Enrolling by invitation only
(pdf – password protected) |
PI: Stephen Oh
Contact: Nicole Gaudin
nrgaudin@wustl.edu
314-747-7960 | Myelofibrosis | A Phase 2 Dose Expansion Study of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis (MANIFEST) (Constellation Pharmaceuticals) | Ongoing; closed to enrollment
(pdf – password protected) |
PI: Stephen Oh
Contact: Karyn Gordon
kdgordon@wustl.edu
314-362-0156 | Myelofibrosis | Phase 2 Study of KRT-232 in Myelofibrosis Patients Who Failed Prior JAK Inhibitor (Kartos Therapeutics) | Open to enrollment
(pdf – password protected) |
PI: Stephen Oh
Contact: Karyn Gordon
kdgordon@wustl.edu
314-362-0156 | Myelofibrosis | A Phase 1/2 study of INCB000928 ± Ruxolitinib in Myelofibrosis Patients with Anemia (INCB 00928-104) (Incyte Corp) | Open to enrollment
(pdf – password protected) |
PI: Stephen Oh
Contact: Nicole Gaudin
nrgaudin@wustl.edu
314-747-7960 | Essential Thrombocythemia | A Phase 3 Study of P1101 vs Anagrelide in Essential Thrombocythemia Patients who Failed Hydroxyurea (P1101ET) (PharmaEssentia Corp) | Open to enrollment
(pdf – password protected) |
PI: Stephen Oh
Contact: Nicole Gaudin
nrgaudin@wustl.edu
314-747-7960 | Essential Thrombocythemia | A Phase 2b Open Label Study of Ropeginterferon (P1101) in Essential Thrombocythemia Patients (PharmaEssentia) | Pending Open
(pdf – password protected) |
PI: Stephen Oh
Contact: Karyn Gordon
kdgordon@wustl.edu
314-362-0156 | Myelofibrosis | A Phase 3 Study of Pelabresib (CPI-0610) plus Ruxolitinib vs Placebo plus Ruxolitinib in Myelofibrosis Patients (Constellation Pharmaceuticals) | Ongoing; closed to enrollment
(pdf – password protected) |
PI: Stephen Oh
Contact: Nicole Gaudin
nrgaudin@wustl.edu
314-747-7960 | Systemic Mastocytosis | A Phase 2 Study of CGT9486 in Patients with Nonadvanced Systemic Mastocytosis (Summit) (Cogent Biosciences) | Open to enrollment
(pdf – password protected) |
PI: Stephen Oh
Contact: Nicole Gaudin
nrgaudin@wustl.edu
314-747-7960 | Systemic Mastocytosis | A Phase 2 Study of Avapritinib (BLU-285) in Nonadvanced Systemic Mastocytosis Patients with Inadequately Controlled Symptoms (BLU-285-2203) (Blueprint Medicines) | Ongoing; closed to enrollment
(pdf – password protected) |
PI: Stephen Oh
Contact: Karyn Gordon
kdgordon@wustl.edu
314-362-0156 | Polycythemia Vera | A Phase 2a Study of ISIS 702843 in Phlebotomy Dependent Polycythemia Vera Patients (ISIS 702843-CS4) (Ionis Pharmaceuticals) | Open to enrollment
(pdf – password protected) |
PI: Stephen Oh
Contact: Karyn Gordon
kdgordon@wustl.edu
314-362-0156 | Polycythemia Vera | A Phase 3b Study of Ropeginterferon (P1101) in Polycythemia Vera Patients (PharmaEssentia) | Pending Open
(pdf – password protected) |
PI: Sana Saif Ur Rehman
Contact: Isuru Gamlath
isuru.gamlath@wustl.edu
314-362-9998 | Sickle Cell Disease | Patient Characteristics and Treatment Patterns from Early Crizanlizumab Use in Real-world Setting (National Alliance of Sickle Cell Centers) | (pdf – password protected) |
PI: Sana Saif Ur Rehman
Contact: Isuru Gamlath
isuru.gamlath@wustl.edu
314-362-9998 | Sickle Cell Disease | Globin research Network for DATA and Discovery (GRNDaD) (Global Blood Therapeutics) | (pdf – password protected) |
PI: Sana Saif Ur Rehman
Contact: Isuru Gamlath
isuru.gamlath@wustl.edu
314-362-9998 | Sickle Cell Disease | Globin research Network for DATA and Discovery (GRNDaD) substudy – HUGS (Global Blood Therapeutics) | (pdf – password protected) |
PI: Kristen Sanfilippo
Contact: Kim Kramer
kramerka@wustl.edu
314-273-1790 | Blood clots in cancer patients | A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effects of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ANT-007) (Anthos Therapeutics) | Open to enrollment
(pdf – password protected) |
PI: Kristen Sanfilippo
Contact: Kim Kramer
kramerka@wustl.edu
314-273-1790 | Blood clots in cancer patients | A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI) / genitourinary (GU) cancer associated VTE (ANT-008) (Anthos Therapeutics) | Open to enrollment
(pdf – password protected) |
PI: Amy Zhou
Contact: Nicole Gaudin
nrgaudin@wustl.edu
314-747-7960 | Myelofibrosis | A Phase 1b/2a Study of DISC-0974 in Myelofibrosis Patients with Anemia (DISC-0974-102) (DISC Medicine) | Pending open
(pdf – password protected) |